CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital Universitario de Donostia
San Sebastián, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario de Donostia (34)
2024
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
2023
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
2022
2021
-
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
PLoS ONE, Vol. 16, Núm. 10 October
-
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Computer Methods and Programs in Biomedicine, Vol. 208
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)
Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)
Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
2019
-
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243
2017
-
Contribution of different relapse phenotypes to disability in multiple sclerosis
Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276
-
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203
-
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response
Brain, Vol. 140, Núm. 9, pp. 2426-2443
2016
-
Defining secondary progressive multiple sclerosis
Brain, Vol. 139, Núm. 9, pp. 2395-2405
-
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3
-
Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score
Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150
-
Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS
Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569